ОСОБЛИВОСТІ ЕПІТЕЛІАЛЬНО-МЕЗЕНХІМАЛЬНОГО ПЕРЕХОДУ В КАРЦИНОМАХ ЕНДОМЕТРІЯ
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16982Ключові слова:
ендометріоїдна карцинома ендометрію, епітеліально-мезенхімальний перехід, транскрипційні фактори, Snail, Twist, ZEB.Анотація
Резюме. Епітеліально-мезенхімальний перехід є важливою складовою прогресування пухлинного процесу, за допомогою нього клітини злоякісних новоутворень набувають інвазивних і міграційних властивостей. Аналіз літературних джерел і дані власних досліджень свідчать, що активація білків, які залучені до епітеліально-мезенхімального переходу, безумовно, впливає на прогресування карциноми ендометрія, і саме значна варіабельність їх експресії може зумовлювати клінічну і морфологічну гетерогенність цієї форми раку. Найбільш агресивні пухлини характеризуються гібридним епітеліально-мезенхімальним фенотипом, який часто асоціюється з колективним типом інвазії пухлинних клітин ендометрія у міометрій.
Посилання
Fedorenko ZP, Mikhailovich YU, Gulak LO, et al. Cancer in Ukraine, 2019-2020. Morbidity, mortality, indicators of oncology service activity. Bul Nat Registry of Ukraine 2021; 22: 82 p. http://www.ncru.inf.ua
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics 2021. CA. Cancer J Clin 2021; 71: 7–33. https://doi.org/10.3322/caac.21654
Nyen TV, Moiola CP, Colas E, et al. Modeling endometrial cancer: past, present, and future. Іnt J Mol Sci 2018; 19: 2348. https://doi.org/10.3390/ijms19082348
Francou A, Anderson KV. The epithelial-to-mesenchymal transition in development and cancer. Annu Rev Cancer Biol 2020; 4: 197–220. https://doi.org/10.1146/annurev-cancerbio-030518-055425
Qin J-H, Wang L, Li Q-L, et al. Epithelial-mesenchymal transition as strategic microenvironment mimicry for cancer cell survival and іmmune escape? Genes Dis 2017; 4: 16–8. https://doi.org/10.1016/j.gendis.2016.10.001
Jolly MK, Ware KE, Gilja S, et al. EMT and MET: Ne¬cessary or permissive for metastasis? Mol Oncol 2017; 11: 755–69. https://doi.org/10.1002/1878-0261.12083
Williams ED, Gao D, Redfern A, Thompson EW. Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nat Rev Cancer 2019; 19: 716–32. https://doi.org/10.1038/s41568-019-0213-x
Bhatia S, Wang P, Toh A, Thompson EW. New insights into the role of phenotypic plasticity and EMT in driving cancer progression. Front Mol Biosci 2020; 7: 71.https://doi.org/10.3389/fmolb.2020.00071
Chaffer CL, Juan BPS, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev 2016; 35: 645–54. https://doi.org/10.1007/s10555-016-9648-7
Liao T-T, Yang M-H. Hybrid epithelial/mesenchymal state in cancer metastasis: clinical significance and regulatory mechanisms. Cells 2020; 9: 623. https://doi.org/10.3390/cell9030623
Tolibova GKh, Tral TG, Ailamazyan EK, et al. Molecular mechanisms of cyclic transformation of the endometrium. J Obstetrics Women’s Dis 2019; 68: 5–12:https://doi.org/10.17816/JOWD6815-12 (in Russian)
Sanderson PA, Critchley HO, Williams AR, et al. New concepts for an old problem: The diagnosis of endometrial hyperplasia. Hum Reprod Update 2017; 23: 232–54. https://doi.org/10.1093/humupd/dmw042
Chiu H-C, Li C-J, Yiang G-T, et al. Epithelial to mesenchymal transition and cell biology of molecular regulation in endometrial carcinogenesis. J Clin Med 2019; 8: 439. https://doi.org/10.3390/jcm8040439
Buchynska LG, Borykun TV, Iurchenko NP, et al. Еxpression of microRNA in tumor cells of endmetrioid carcinoma of endometrium. Exp Oncol 2020; 42: 289–94. https://doi.org/10.32471/exp-oncology.2312-8852
Škovierová H, Okajčeková T, Strnádel J, et al. Molecular regulation of epithelial to mesenchymal transition in tumorigenesis (Review). Int J Mol Med 2018; 41: 1187–200. https://doi.org/10.3892/ijmm.2017.3320
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–96. https://doi.org/10.1038/nrm3758
Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol 2020; 13: 100773. https://doi.org/10.1016/j.tranon.2020.100773
Kang E, Seo J, Yoon H, Cho S. The post-translational regulation of epithelial–mesenchymal transition-inducing transcription factors in cancer metastasis. Int J Mol Sci 2021: 22: 3591.https://doi.org/10.3390/ijms22073591
Huang L, Jin Y, Feng S, et al. Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer. Exp Ther Med 2016; 12: 3851–8. https://doi.org/10.3892/etm.2016.3885
Makker A, Goel MM. Tumor progression, metastasis, and modulators of epithelial–mesenchymal transition endometrioid endometrial carcinoma: an update. Endocr Relat Cancer 2016; 23: 85–111. https://doi.org/10.1530/ERC-15-0218
McMellen A, Woodruff ER, Corr BR, et al. Wnt signaling in gynecologic malignancies. J Mol Sci 2020; 21: 4272. https://doi.org/10.3390/ijms21124272
Goad J, Ko YA, Kumar M, et al. Oestrogen fuels the growth of endometrial hyperplastic lesions initiated by overactive Wnt/β-catenin signalling. Carcinogenesis 2018; 39: 1105–16. https://doi.org/10.1093/carcin/bgy079
Kasoha M, Dernektsi C, Seibold A, et al. Crosstalk of estrogen receptors and Wnt/β-catenin signaling in endometrial cancer. Cancer Res Clin Oncol 2020; 146: 315–27. https://doi.org/10.1007/s00432-019-03114-8
Wang Y, Hanifi-Moghaddam P, Hanekamp EE, et al. Progesterone inhibition of Wnt/β-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 2009; 15: 5784–93. https://doi.org/10.1158/1078-0432.CCR-09-0814
Ahmadi A, Najafi M, Farhood B, Mortezaee K. Transforming growth factor β signalling: Tumorigenesis and targeting for cancer therapy. J Cell Physiol 2019; 234: 12173–87. https://doi.org/10.1002/jcp.27955
Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-β-induced epithelial–mesenchymal transition. Curr Оpin Сell Вiol 2014; 31: 56–66. https://doi.org/10.1016/j.ceb.2014.09.001
Bokhari AA, Lee LR, Raboteau D, et al. Progeste¬rone inhibits endometrial cancer invasiveness by inhibiting the TGF-β pathway. Cancer Prev Res 2014; 7: 1045–55. https://doi.org/10.1158/1940-6207.CAPR-14-0054
Paucarmayta A, Taitz H, Casablanca Y, et al. TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types. Transl Cancer Res 2019; 8: 1423–37. doi: org/10.21037/tcr.2019.07.36
Fatima I, Barman S, Rai R, et al. Targeting Wnt signaling in endometrial cancer. Cancers (Basel) 2021; 13: 2351.https://doi.org/10.3390/cancers13102351
Kurnit KC, Draisey A, Kazen RC, et al. Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer. Cancer Let 2021; 505: 75–86. https://doi.org/10.1016/j.canlet.2021.01.030
Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The emerging role of the microenvironment in endometrial cancer, Cancers (Basel) 2018; 10: 408. https://doi.org/10.3390/cancers10110408
Subramaniam KS, Omar IS, Kwong SC, et al. Cancer associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway. Am J Cancer Res 2016; 6: 200–13: http://www.ajcr.us/ISSN:2156-6976/ajcr0021359
Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 2019; 26: 78. https://doi.org/10.1186/s12929-019-0568-z
Li M, Xin X, Wu T, et al. Stromal cells of endometrial carcinoma promotes proliferation of epithelial cells through the HGF/c-Met/Akt signaling pathway. Tumour Biol 2015; 36: 6239–48. https://doi.org/10.1007/s13277-015-3309-2
Buchynska LG, Movchan OM, Iurchenko NP. Expression of chemokine receptor CXCR4 in tumor cells and content of CXCL12+-fibroblasts in endometrioid carcinoma of endometrium. Exp Oncol 2021; 43: 135–41. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16240
Yoriki K, Mori T, Kokabu T, et al. Estrogen-related receptor alpha induces epithelial-mesenchymal transition through cancer-stromal interactions in endometrial cancer. Sci Rep 2019; 9: 6697.https://doi.org/10.1038/s41598-019-43261-z
Chen H-Y, Chiang Y-F, Huang J-S, et al. Isoliquiritigenin reverses epithelial-mesenchymal transition through modulation of the TGF-β/Smad signaling pathway in endometrial cancer. Cancers (Basel) 2021; 13: 1236.https://doi.org/10.3390/cancers13061236
Romeo E, Caserta CA, Rumio C, Marcucci F. The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system. Cells 2019; 8: 460. https://doi.org/10.3390/cells8050460
Dhanasekaran R, Baylot V, Kim M, et al. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Cancer Biol 2020; 14: 202. https://doi.org/10.7554/eLife.50731
Nesina I, Iurchenko N, Nespriadko S, Buchynska L. Twist expression and content of tumour-associated macrophages in endometrial carcinoma. Oncol Clin Pract 2021; 17: 139–47. https://doi.org/10.5603/OCP.2021.0026
Abba ML, Patil N, Leupold JH, Allgayer H. MicroRNA regulation of epithelial to mesenchymal transition. J Clin Med 2016; 5: 8. https://doi.org/10.3390/jcm5010008
Zaravinos A. The regulatory role of microRNAs in EMT and cancer. J Оncol 2015; 2015: 865816. https://doi.org/10.1155/2015/865816
Deng J, Wang W, Yu G, Mа X. MicroRNA-195 inhibits epithelial-mesenchymal transition by targeting G protein-coupled estrogen receptor 1 in endometrial carcinoma. Mol Med Reports 2019; 20: 4023-32. https://doi.org/10.3892/mmr.2019.10652
Gugnoni M, Ciarrocchi A. Long noncoding RNA and epithelial mesenchymal transition in cancer. J Mol Sci 2019; 20: 1924. https://doi.org/10.3390/ijms20081924
Landeros N, Santoro PM, Carrasco-Avino G, Corvalan AH. Competing endogenous RNA networks in the epithelial to mesenchymal transition in diffuse-type of gastric cancer. Cancers (Basel) 2020; 12: 2741. https://doi.org/10.3390/cancers12102741
Liu W, Zhang B, Xu N, et al. miR-326 regulates EMT and metastasis of endometrial cancer through targeting TWIST1. Eur Rev Med Pharm Sci 2017; 21: 3787–93.
Buchynska LG, Borykun TV, Iurchenko NP, et al. Еxpression of microRNA in tumor cells of endmetrioid carcinoma of endometrium. Exp Oncol 2020; 42: 289–94. https://doi.org/10.32471/exp-oncology.2312-8852
Donkers H, Bekkers R, Galaal K. Diagnostic value of microRNA panel in endometrial cancer: A systematic review. Oncotarget 2020; 11: 2010–23. https://doi.org/10.18632/oncotarget.27601
Piergentili R, Zaami S, Cavaliere AF, et al. Non-coding RNAs as prognostic markers for endometrial cancer. Int J Mol Sci 2021; 22: 3151.https://doi.org/10.3390/ijms2206315
Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer 2016; 15: 18. HTTPS://DOI.ORG/10.1186/s12943-016-0502
Dave N, Guaita-Esteruelas S, Gutarra S, et al Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J Biol Chem 2011; 286: 12024–32. https://doi.org/10.1074/jbc.M110.168625
Xu R, Won J-Y, Kim C-H, et al. Roles of the рhosphorylation of transcriptional factors in epithelial-mesenchymal transition. J Oncol 2019; ID: 5810465:https://doi.org/10.1155/2019/5810465
Lin Y, Wang Y, Shi Q, et al. Stabilization of the transcription factors Slug and Twist by the deubiquitinase Dub3 is a key requirement for tumor metastasis. Oncotarget 2017; 8: 75127–40: https://doi.org/10.18632/oncotarget.20561
Sreekumar R, Al-Saihati H, Emaduddin M, et al. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer. Mol Oncol 2021; 15: 2065–83. https://doi.org/10.1002/1878-0261.12965
Tanaka Y, Terai Y, Kawaguchi H, et al. Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer. Cancer Biol Ther 2013; 14: 13–9. https://doi.org/10.4161/cbt.22625
Abouhashem NS, Ibrahim DA, Mohamed AM. Prognostic implications of epithelial to mesenchymal transition proteins (E-cadherin, Snail) and hypoxia inducible factor endometrioid endometrial carcinoma. Ann Diagn Pathol 2016; 22: 1–11. https://doi.org/10.1016/j.anndiagpath.2016.01.004
Xie X, Zheng X, Wang J, Chen L. Clinical significance of Twist, E-cadherin, and N-cadherin protein expression in endometrioid adenocarcinoma. J Can Res Ther 2017; 13: 817–22.https://doi.org/10.1155/2019/5810465
Feng Z, Gan H, Cai Z, et al. Aberrant expression of hypoxia-inducible factor 1α, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma. Jpn J Clin Oncol 2013; 43: 396–403. https://doi.org/10.1093/jjco/hys237
Senol S, Sayar I, Ceyran AB, et al. Stromal clues in endometrial carcinoma: loss of expression of β-catenin, epithelial-mesenchymal transition regulators, and estrogen-progesterone receptor. Int J Gynecol Pathol 2016; 35: 238–48. doi:10:1097/PGP:0000000000000233
Sadłecki P, Jóźwicki J, Antosik P, Walentowicz-Sadłecka M. Expression of selected epithelial-mesenchymal transition transcription factors in endometrial cancer. Biomed Res Intern 2020; 2020: 4584250.https://doi.org/10.1155/2020/4584250
Krögera C, Afeyana A, Mraz J, et al. Acquisition of a hybrid E/M state is essential fortumorigenicity of basal breast cancer cells. PNAS 2019; 116: 7353–62. doi/10.1073/pnas.1907473116
Roberta R-M, Emina B, Danijela V-M, et al. The immunohistochemical pattern of epithelial-mesenchymal transition markers in endometrial carcinoma. Appl IHC Mol Morph 2020; 28: 339–46. https://doi.org/10.1097/PAI.0000000000000754
Buchynska LG, Naleskina LА, Nesina IP. Morphological characteristics and expression features of adhesion markers in cells of low differentiated endometrial carcinoma. Exp Oncol 2019; 41: 335–41. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13965
Wilson MR, Reske JJ, Holladay J, et al. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nat Commun 2019; 10: 3554.https://doi.org/10.1038/s41467-019-11403-6
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Експериментальна онкологія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
